MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
  •  
  • September 2017

Renowned Dermatologist Dr. Michael H. Gold Joins AIVITA Scientific Advisory Board

AIVITA Biomedical Announces New Discovery with Applications to Regenerative Medicine, Skin Aging and Hair Growth

AIVITA Biomedical Announces New Discovery with Applications to Regenerative Medicine, Skin Aging and Hair Growth Read more to find…

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
  • AIVITA Biomedical Closes $25 Million Financing Round
  • AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
  • AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
  • AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.